Walker et al. (2) reviewed information gathered between 1991 and 1993 from the Clozaril National Registry of 67,072 patients. The group found that the relative risk of dying from a pulmonary embolus increased by a factor of 5.2 when comparing current users with former users of the medication. This made it the second most common cause of death among current clozapine users, with only death through external causes (accident, homicide, and suicide) occurring more frequently. Looking at all reported adverse reactions among clozapine patients in Sweden between April 1, 1989, and March 1, 2000, Hagg et al. (3) found six cases of pulmonary emboli and six cases of venous thrombosis. They concluded that clozapine might be associated with venous thromboembolism; the risk was highest in the first 3 months of treatment. Despite these interesting epidemiological findings, we know of only two published case reports of pulmonary embolus in clozapine patients (4, 5), both of which described patients with additional independent risk factors for pulmonary embolus. Known risk factors for thromboembolic disease include genetic factors (mainly the factor V Leiden mutation or a high concentration of factor VIII), recent immobilization, recent surgery, pregnancy or the postpartum state, and obesity (6).